Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dacetuzumab in relapsed DLBCL
NCT00435916Phase 2Completed
- Sponsor
- Seagen Inc.
- Start
- Dec 2006
- Primary completion
- Jan 2009
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dacetuzumab in diffuse large B-cell lymphoma (DLBCL), sponsored by Seagen Inc. Primary endpoint: Objective Response Rate. Started Dec 2006; status: completed.
02
Drugs
dacetuzumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00435916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00435916.